Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Tuesday.
Several other equities analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, March 19th. ValuEngine raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Finally, Leerink Swann started coverage on shares of Adaptimmune Therapeutics in a report on Friday, March 16th. They set a “buy” rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $11.58.
Shares of ADAP stock opened at $12.39 on Tuesday. The company has a market cap of $1,158.01, a P/E ratio of -15.49 and a beta of 1.19. Adaptimmune Therapeutics has a 52-week low of $4.28 and a 52-week high of $13.41.
Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.04). The business had revenue of $4.27 million for the quarter, compared to analysts’ expectations of $9.38 million. Adaptimmune Therapeutics had a negative net margin of 185.39% and a negative return on equity of 32.26%. equities analysts predict that Adaptimmune Therapeutics will post -0.82 EPS for the current year.
In other Adaptimmune Therapeutics news, CFO Adrian Rawcliffe sold 600,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 20th. The shares were sold at an average price of $1.71, for a total value of $1,026,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David M. Mott bought 869,574 shares of the stock in a transaction on Thursday, March 22nd. The stock was purchased at an average price of $1.90 per share, with a total value of $1,652,190.60. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 9,385,254 shares of company stock valued at $17,966,655. 24.45% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in ADAP. OxFORD Asset Management LLP boosted its stake in Adaptimmune Therapeutics by 30.1% in the third quarter. OxFORD Asset Management LLP now owns 45,238 shares of the biotechnology company’s stock valued at $369,000 after acquiring an additional 10,471 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Adaptimmune Therapeutics in the third quarter valued at approximately $182,000. Creative Planning lifted its stake in shares of Adaptimmune Therapeutics by 66.7% during the fourth quarter. Creative Planning now owns 66,681 shares of the biotechnology company’s stock worth $445,000 after buying an additional 26,681 shares during the period. Alps Advisors Inc. lifted its stake in shares of Adaptimmune Therapeutics by 12.7% during the fourth quarter. Alps Advisors Inc. now owns 103,816 shares of the biotechnology company’s stock worth $693,000 after buying an additional 11,716 shares during the period. Finally, Essex Investment Management Co. LLC lifted its stake in shares of Adaptimmune Therapeutics by 19.6% during the fourth quarter. Essex Investment Management Co. LLC now owns 87,307 shares of the biotechnology company’s stock worth $583,000 after buying an additional 14,311 shares during the period. Institutional investors own 55.50% of the company’s stock.
WARNING: This story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/19/bidaskclub-upgrades-adaptimmune-therapeutics-adap-to-buy.html.
Adaptimmune Therapeutics Company Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.